Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 6c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
February 28, 2023 4:05 PM ESTFull-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range
Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021
Full-year 2023 revenue is expected to be between $170-180 million
Conference call and webcast today at 4:30 p.m. ET
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and twelve months ended Dec. 31,... More
